おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Aprea
company
About
Aprea focuses on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53.
- 1 - 10
Highlights
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- €50M
- Industries
- Biotechnology,Health Care,Medical,Personal Health,Pharmaceutical
- Founded date
- Jan 1, 2003
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Aprea is a Swedish biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea's main shareholder is KDev Investments AB, an investment vehicle owned by Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital Ltd. Other shareholders include Östersjöstiftelsen, Praktikerinvest, and KCIF Co-Investment Fund KB.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
€96M
Aprea has raised a total of
€96M
in funding over 2 rounds. Their latest funding was raised on
Nov 30, 2018 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 30, 2018 | Series C | €50M | 1 | — | — | Detail |
| Mar 9, 2016 | Series B | €46M | 1 |
Versant Ventures
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Aprea is funded by 1 investors.
Versant Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Versant Ventures
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
